{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:01:13Z","timestamp":1782432073412,"version":"3.54.5"},"reference-count":19,"publisher":"AVES YAYINCILIK A.\u015e.","issue":"4","license":[{"start":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T00:00:00Z","timestamp":1735603200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Archives of Rheumatology"],"abstract":"<jats:p>Objectives: This study aimed to evaluate levels of fecal calprotectin (FC), a biomarker that helps distinguish irritable bowel syndrome from inflammatory gut disorders, in patients with fibromyalgia syndrome (FMS) and compare them to healthy controls.\r\n Patients and methods: The cross-sectional study was carried out on patients diagnosed with FMS according to the ACR (American College of Rheumatology) 2016 classification and healthy controls between January 2021 and February 2022. FMS patients were grouped according to the absence (Group 1) or presence (Group 2) of gastrointestinal symptoms. A third group of healthy controls without gastrointestinal complaints (Group 3) was included. Demographic data, comorbidities, medications, symptom severity scale, and widespread pain index scores were recorded. All subjects were asked to provide stool samples for the measurement of FC levels.\r\n Results: A total of 100 subjects were included in the study. There were 33 patients (4 males, 29 females, mean age: 46.9\u00b110.6; range, 22 to 69 years) in Group 1, 32 patients (2 males, 30 females, mean age: 48.5\u00b111.0; range, 22 to 73 years) in Group 2, and 35 patients (11 males, 24 females, mean age: 39.2\u00b113.1; range, 22 to 67 years) in Group 3. Group 2 had significantly higher levels of FC compared to Group 3 (p&lt; 0.05). The number of patients with positive FC values was similar between the three groups. Symptom severity scale and widespread pain index scores were significantly worse in Group 2 compared to Group 1 (p&lt; 0.05).\r\n Conclusion: Irritable bowel syndrome usually coexists in many patients with FMS, and this may cause a misdiagnosis or delay in the diagnosis of organic gastrointestinal conditions. The value of FC in screening and diagnosis of organic disease in FMS patients needs further evaluation.<\/jats:p>","DOI":"10.46497\/archrheumatol.2024.10557","type":"journal-article","created":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T07:56:27Z","timestamp":1740988587000},"page":"522-528","source":"Crossref","is-referenced-by-count":1,"title":["Fecal calprotectin levels in patients with fibromyalgia: A cross-sectional study"],"prefix":"10.5152","volume":"39","author":[{"family":"Ece \u00c7\u0131nar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Meryem Burcu T\u00fcrko\u011flu Aytar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Musa Baklac\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Simin Hepg\u00fcler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Burcu Barut\u00e7uo\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3111","published-online":{"date-parts":[[2024,12,31]]},"reference":[{"key":"ref-1","unstructured":"H\u00e4user W, Sarzi-Puttini P, Fitzcharles MA. Fibromyalgia syndrome: Under-, over- and misdiagnosis. Clin Exp Rheumatol 2019;37 Suppl 116:90-7."},{"key":"ref-2","doi-asserted-by":"crossref","unstructured":"Kleykamp BA, Ferguson MC, McNicol E, Bixho I, Arnold LM, Edwards RR, et al. The prevalence of psychiatric and chronic pain comorbidities in fibromyalgia: An ACTTION systematic review. Semin Arthritis Rheum 2021;51:166-74. doi: 10.1016\/j. semarthrit.2020.10.006.","DOI":"10.1016\/j.semarthrit.2020.10.006"},{"key":"ref-3","doi-asserted-by":"crossref","unstructured":"Guo J, Pei L, Chen L, Chen H, Gu D, Peng Y, et al. Bidirectional association between irritable bowel syndrome and restless legs syndrome: A systematic review and meta-analysis. Sleep Med 2021;77:104-11. doi: 10.1016\/j.sleep.2020.12.002.","DOI":"10.1016\/j.sleep.2020.12.002"},{"key":"ref-4","doi-asserted-by":"crossref","unstructured":"Gemignani F. Irritable bowel syndrome, restless legs syndrome, small fiber neuropathy, and fibromyalgia. Sleep Med 2021;83:4. doi: 10.1016\/j. sleep.2021.04.023.","DOI":"10.1016\/j.sleep.2021.04.023"},{"key":"ref-5","doi-asserted-by":"crossref","unstructured":"Erdrich S, Hawrelak JA, Myers SP, Harnett JE. A systematic review of the association between fibromyalgia and functional gastrointestinal disorders. Therap Adv Gastroenterol 2020;13:1756284820977402. doi: 10.1177\/1756284820977402.","DOI":"10.1177\/1756284820977402"},{"key":"ref-6","doi-asserted-by":"crossref","unstructured":"Smalley W, Falck-Ytter C, Carrasco-Labra A, Wani S, Lytvyn L, Falck-Ytter Y. AGA clinical practice guidelines on the laboratory evaluation of functional diarrhea and diarrhea-predominant Irritable Bowel Syndrome in Adults (IBS-D). Gastroenterology 2019;157:851-4. doi: 10.1053\/j. gastro.2019.07.004.","DOI":"10.1053\/j.gastro.2019.07.004"},{"key":"ref-7","doi-asserted-by":"crossref","unstructured":"Sayuk GS, Wolf R, Chang L. Comparison of symptoms, healthcare utilization, and treatment in diagnosed and undiagnosed individuals with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 2017;112:892-9. doi: 10.1038\/ajg.2016.574.","DOI":"10.1038\/ajg.2016.574"},{"key":"ref-8","doi-asserted-by":"crossref","unstructured":"Wolfe F, Clauw DJ, Fitzcharles MA, Goldenberg DL, H\u00e4user W, Katz RL, et al. 2016 Revisions to the 2010\/2011 fibromyalgia diagnostic criteria. Semin Arthritis Rheum 2016;46:319-29. doi: 10.1016\/j. semarthrit.2016.08.012.","DOI":"10.1016\/j.semarthrit.2016.08.012"},{"key":"ref-9","doi-asserted-by":"crossref","unstructured":"Husebye E, T\u00f8n H, Johne B. Biological variability of fecal calprotectin in patients referred for colonoscopy without colonic inflammation or neoplasm. Am J Gastroenterol 2001;96:2683-7. doi: 10.1111\/j.1572- 0241.2001.04126.x.","DOI":"10.1016\/S0002-9270(01)02688-0"},{"key":"ref-10","doi-asserted-by":"crossref","unstructured":"Ayling RM, Kok K. Fecal calprotectin. Adv Clin Chem 2018;87:161-90. doi: 10.1016\/bs.acc.2018.07.005.","DOI":"10.1016\/bs.acc.2018.07.005"},{"key":"ref-11","doi-asserted-by":"crossref","unstructured":"D'Amico F, Rubin DT, Kotze PG, Magro F, Siegmund B, Kobayashi T, et al. International consensus on methodological issues in standardization of fecal calprotectin measurement in inflammatory bowel diseases. United European Gastroenterol J 2021;9:451-60. doi: 10.1002\/ueg2.12069.","DOI":"10.1002\/ueg2.12069"},{"key":"ref-12","doi-asserted-by":"crossref","unstructured":"Kulshreshtha P, Deepak KK. Autonomic nervous system profile in fibromyalgia patients and its modulation by exercise: A mini review. Clin Physiol Funct Imaging 2013;33:83-91. doi: 10.1111\/ cpf.12000.","DOI":"10.1111\/cpf.12000"},{"key":"ref-13","doi-asserted-by":"crossref","unstructured":"Lacy BE, Patel NK. Rome Criteria and a diagnostic approach to irritable Bowel Syndrome. J Clin Med 2017;6:99. doi: 10.3390\/jcm6110099.","DOI":"10.3390\/jcm6110099"},{"key":"ref-14","doi-asserted-by":"crossref","unstructured":"Park S. Age-related fecal calprotectin concentrations in healthy adults. Korean J Clin Lab Sci 2020;52:181-7.","DOI":"10.15324\/kjcls.2020.52.3.181"},{"key":"ref-15","doi-asserted-by":"crossref","unstructured":"Simioni J, Skare TL, Campos APB, Kotze L, MessiasReason I, Ioshii SO, et al. Fecal calprotectin, gut inflammation and spondyloarthritis. Arch Med Res 2019;50:41-6. doi: 10.1016\/j.arcmed.2019.04.003.","DOI":"10.1016\/j.arcmed.2019.04.003"},{"key":"ref-16","doi-asserted-by":"crossref","unstructured":"Ojetti V, Saviano A, Covino M, Acampora N, Troiani E, Franceschi F, et al. COVID-19 and intestinal inflammation: Role of fecal calprotectin. Dig Liver Dis 2020;52:1231-3. doi: 10.1016\/j.dld.2020.09.015.","DOI":"10.1016\/j.dld.2020.09.015"},{"key":"ref-17","doi-asserted-by":"crossref","unstructured":"Park SY, Lee SP, Kim WJ. Fecal calprotectin is increased in stroke. J Clin Med 2021;11:159. doi: 10.3390\/jcm11010159.","DOI":"10.3390\/jcm11010159"},{"key":"ref-18","doi-asserted-by":"crossref","unstructured":"Hor JW, Lim SY, Khor ES, Chong KK, Song SL, Ibrahim NM, et al. Fecal calprotectin in Parkinson's Disease and multiple system atrophy. J Mov Disord 2022;15:106-14. doi: 10.14802\/jmd.21085.","DOI":"10.14802\/jmd.21085"},{"key":"ref-19","doi-asserted-by":"crossref","unstructured":"Caviglia GP, Ribaldone DG, Rosso C, Saracco GM, Astegiano M, Pellicano R. Fecal calprotectin: Beyond intestinal organic diseases. Panminerva Med 2018;60:29-34. doi: 10.23736\/S0031- 0808.18.03405-.","DOI":"10.23736\/S0031-0808.18.03405-5"}],"container-title":["Archives of Rheumatology"],"original-title":[],"link":[{"URL":"https:\/\/archivesofrheumatology.org\/index.php\/pub\/article\/download\/1444\/2580","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/archivesofrheumatology.org\/index.php\/pub\/article\/download\/1444\/2581","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/archivesofrheumatology.org\/index.php\/pub\/article\/download\/1444\/2580","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T09:00:52Z","timestamp":1761210052000},"score":1,"resource":{"primary":{"URL":"https:\/\/archivesofrheumatology.org\/index.php\/pub\/article\/view\/1444"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,31]]},"references-count":19,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,12,31]]}},"URL":"https:\/\/doi.org\/10.46497\/archrheumatol.2024.10557","relation":{},"ISSN":["2618-6500"],"issn-type":[{"value":"2618-6500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,31]]}}}